Atlas
Back to RCM
Peer Fund / Dealmaker·RCM

Ramzi Musallam

CEO and Managing Partner at Veritas Capital

New York, New York, USA

RM
Why they matter

Controls the largest payment-integrity platform in private equity — Cotiviti — plus $15.3B of fresh Fund IX capital, making him both the definitive RCM buyer and the benchmark comp.

Background

Ramzi Musallam is CEO and Managing Partner of Veritas Capital, a New York private equity firm that buys technology-enabled companies in heavily regulated markets — national security, healthcare, education and infrastructure. He joined in 1997 as a founding member of the firm's first institutional fund (1998) and became CEO in 2012, growing assets under management from roughly $2 billion to over $53 billion. He began his career at J.P. Morgan's Structured Finance Division and previously worked at Berkshire Partners and Pritzker & Pritzker; he holds a B.A. in mathematical economics from Colgate and an M.B.A. from Chicago Booth.

Notable deals

  • 2024
    Led Veritas' recapitalization of healthcare data-analytics and payment-integrity company Cotiviti with KKR, taking equal co-sponsor stakes after eight years of Veritas ownership
  • 2019
    Completed the $5.7 billion take-private of athenahealth with Elliott, merging it with Veritas' Virence Health (former GE Healthcare value-based care assets)
  • 2026
    Agreed to acquire a majority stake in Global Healthcare Exchange (GHX), the healthcare supply-chain software platform connecting providers and suppliers
  • 2026
    Closed $15.3 billion across the Fund IX strategy in a constrained fundraising market, spanning the flagship and middle-market Vantage strategies

Call-prep brief

Background

  • Jordanian-born; started at J.P. Morgan structured finance, then Berkshire Partners and Pritzker & Pritzker.
  • Founding member of Veritas Capital's first institutional fund (1998); CEO since 2012.
  • Grew AUM from ~$2B to ~$54B by acquiring technology assets inside heavily regulated markets — defense, national security, healthcare.

Current focus

  • Healthcare data and payment integrity: co-controls Cotiviti with KKR after the May 2024 recapitalization (Veritas first invested via Verscend in 2016), and agreed in January 2026 to take a majority stake in GHX.
  • Closed $15.3B across the Fund IX strategy in February 2026, including a middle-market "Vantage" strategy.

What he cares about

  • Corporate carve-outs and complex separations, then aggressive bolt-ons — the Virence/athenahealth and Peraton/Perspecta playbooks.
  • Proximity to government and regulated payers; he has said the firm keeps "very close proximity to government."
  • Long holds: Cotiviti has been held since 2016 and was recapitalized rather than sold.

Recent moves — Cotiviti's Edifecs acquisition, the GHX agreement, and Peraton's multi-billion-dollar FAA air-traffic-control modernization award.

Potential sensitivities

  • Payment-integrity economics attract provider and political scrutiny; expect guardedness on pricing and on how AI reshapes claim review.
  • The $17B athenahealth exit is the benchmark he is measured against — don't open there.
  • Recap-not-sale structures make Cotiviti's eventual exit path a live and unwelcome question from a stranger.

Three questions to ask

  1. After Edifecs, where does Cotiviti still buy versus build across payment integrity?
  2. What does the GHX thesis assume about provider supply-chain budgets over the next five years?
  3. Which parts of the revenue cycle does he think AI genuinely commoditizes, and which stay defensible?

Outreach draft

Subject
Cotiviti, GHX and RCM consolidation
Mr. Musallam — I lead diligence on healthcare revenue-cycle and payment-integrity assets, and Veritas' path from Verscend through Cotiviti to the KKR recapitalization is the clearest example I've seen of building durable scale in that market. We are evaluating a set of RCM and payer-services targets, and your view on where value is migrating — claim review versus supply chain versus provider-side automation — would sharpen ours considerably. The GHX agreement suggests you see connective tissue across those layers. Would you have 30 minutes in the coming weeks? Happy to work around your schedule and to send our market map beforehand. Best regards, [Your Name] [Firm]

Linked companies

Sources